morolimumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 458284456

| image =

| type = mab

| mab_type = mab

| source = u

| target = RhD

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 202833-07-6

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = R6LF24NKU4

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| chemical_formula =

| molecular_weight =

}}

Morolimumab is a human monoclonal antibody against the human Rhesus factor.{{cite journal | title = Proposed International Nonproprietary Names: Morolimumab | journal = WHO Drug Information | volume = 13 | issue = 1 | date = 1991 | page = 45 | url = http://whqlibdoc.who.int/druginfo/INN_1999_list41.pdf | location = Geneva | publisher = World Health Organization }}{{cite book | vauthors = Pelletier JP, Mukhtar F | chapter = Chapter 16 - Passive Monoclonal and Polyclonal Antibody Therapies | veditors = Maitta RW |title=Immunologic Concepts in Transfusion Medicine |date=2020 |publisher=Elsevier |location=Philadelphia |isbn=978-0-323-67510-9 | doi = 10.1016/B978-0-323-67509-3.00016-0 |page=300 | s2cid = 213508934 }}